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Overview 
 
  Here we propose a new recombination-based assembly standard, optimized to allow for 
efficient cloning of mammalian vectors.   
 
Motivation 
 
  Standard biobrick assembly is a useful tool in the process of cloning an expression 
vector; however, it is not an optimal procedure. Issues stemming from the use of 
restriction digestions prevent this process from working well with mammalian constructs; 
it is also a fairly time-intensive process. Our goal was to find a new assembly standard 
that would allow for efficient cloning of the longer sequences encountered in mammalian 
constructs, and attempt to improve on the efficiency of the previous system.   
  Recombination cloning is a quick and efficient process, already widely used in scientific 
community as a protocol for vector assembly. Invitrogen has standardized and simplified 
this process; their system, Gateway® Cloning, involves the use of two different 
bacteriophage recombination enzymes to allow for the assembly of an expression vector 
from two ‘part’-containing vectors. This process is extremely robust (up to 99% 
recombination efficiency), and circumvents many of the more laborious steps involved in 
traditional restriction cloning, such as separate ligation and digestion procedures.  
 
MammoBlock Flanking Sequence Standards 
 
One of the advantages of the MammoBlock standard is the variety of construction 
methods available to assemble the component parts. In standard BioBrick assembly, 
‘components’ are created with flanking restriction sites, then digested and ligated into the 
appropriate backbone. This approach can still be used to create MammoBlock parts; 
however, other methods including recombination cloning can be easily adapted to create 
the appropriate entry vectors.  
 
The restrictions on appropriate MammoBlock parts only involve the sequence of the final 
entry vector; we require that the entry vector contain the construct of interest, flanked by 
two specific Gateway© recombination sites. There are two entry vector categories, one 
for promoter and one for gene inserts.  A specific pair of recombination sites is associated 
with each entry vector standard; see the specifications below.  
 
 
 
 
 
 
 
 
L4R1 Promoter Entry Vector 
 
The promoter entry vectors are characterized by attL4 and attR1 recombination sites 
flanking the insert; this design places the promoter directly in front of the gene after a 
multisite Gateway© reaction. We require that a MammoBlock L4R1 promoter entry 
vector have the following sequence structure around the insert. Note that here we define 
the ‘part’ as the entire region between the flanking attL4 and attR1 sites.    
 
5’ _attL4 site_--------Insert--------_attR1_site_3’ 
 
att_L4 Recombination Site Sequence:  
 
5’CAAATAATGATTTTATTTTGACTGATAGTGACCTGTTCGTTGCAACAAATTGATAAG 
CAATGCTTTTTTATAATGCCAACTTTGTATAGAAAAGTTG 3’ 
 
att_R1 Recombination Site Sequence:  
 
5’CCAAGTTTGTACAAAAAAGTTGAACGAGAAACGTAAAATGATATAAATATCAATATA
TTAAATTAGATTTTGCATAAAAAACAGACTACATAATACTGTAAAACACAACATATGCA
GTCACTATG 3’ 
 
Below is the L4R1 MammoBlock promoter entry vector for the inducible TRE promoter. 
We submit this vector, with biobrick designation pSB1K15 as the first MammoBlock 
backbone for promoter entry vectors.  
 
 
 
Insert ‘Part’ Sequencing Primers for pSB1K15: 
 
M13 (-20) forward primer:   5’CATTTTGCTGCCGGTC 3’ 
M13 reverse primer: 5’CAGGAAACAGCTATGAC 3’ 
                                           
pSB1K15 Bacterial Antibiotic Resistance: Kanamycin 
 
L4R1 Entry Vector Assembly  
 
One noteworthy feature of the the L4R1 backbone plasmid above is the existence of 
convenient directional restriction sites between the recombination sites and the promoter 
sequence; these are not a required feature of MammoBlock backbones, but they can 
simplify entry vector construction. The following is an optional method for restriction 
cloning promoters into the pSB1K15 backbone.  
 
Insert ‘parts’ for this cloning procedure should be fabricated in the following format: 
 
                 PacI          BsrgI 
5’AGTCTTAATTAA—Insert—CGACCCAAGTTTGTACAAGTC 3’ 
3’TCAGAATTAATT—Insert—GCTGGGTTCAAACATGTTCAG 5’ 
     attR1 fragment  
 
BsrgI cuts inside the attR1 recombination site; the fragment in the digested insert replaces 
the cut portion of attR1.  
 
Digestion of pSB1K15 with PacI and BsrgI yields ‘sticky’ ends of the form 
 
5’AGTTTGGTTAAT      GTACAAAAAAGT3’  
3’TCAAACCAAT            TTTTTTCA5’ 
 
between the attL4 and attR1 recombination sites, respectively. Cutting the insert with 
PacI and BsrgI and ligating into digested vector yield the final product:  
 
5’AGTTTGGTTAATTAA—Insert—CGACCCAAGTTTGTACAAAAAAGT3’  
3’TCAAACCAATTAATT—Insert—GCTGGGTTCAAACATGTTTTTTCA5’ 
 
Note that this cloning step is directional; the ligation will yield a promoter in the correct 
orientation.  
 
L1L2 Gene Entry Vector 
 
MammoBlock gene entry vectors are defined by the presence of attL1 and attL2 
recombination sites flanking the gene insert. We require that MammoBlock L1L2 Gene 
Vectors contain the following sequence structure around the insert (or ‘part’), which 
allow for insertion of the gene directly in behind the promoter during the Gateway© 
reaction :  
 
5’ _attL1 site_--------Insert--------_attL2 site_3’ 
 
att_L1 Recombination Site Sequence:  
 
5’CAAATAATGATTTTATTTTGACTGATAGTGACCTGTTCGTTGCAACAAATTGATGAG
CAATGCTTTTTTATAATGCCAACTTTGTACAAAAAAGCAGGCT3’ 
 
 
 
att_L2 Recombination Site Sequence:  
 
5’ACCCAGCTTTCTTGTACAAAGTTGGCATTATAAGAAAGCATTGCTTATCAATTTGTT
GCAACGAACAGGTCACTATCAGTCAAAATAAAATCATTATTTG3’ 
 
An example is shown below of an L1L2 MammoBlock part containing the gene 
fluorescent protein EGFP. We submit this vector, with biobrick designation pSB1K16 as 
the first MammoBlock backbone for promoter entry vectors. 
 
Insert ‘Part’ Sequencing Primers for pSB1K16:  
 
M13 (-20) forward primer:   5’CATTTTGCTGCCGGTC 3’ 
M13 reverse primer: 5’CAGGAAACAGCTATGAC 3’ 
 
pSB1K16 Bacterial Antibiotic Resistance: Kanamycin 
 
 
 
 
 
 
 
MammoBlock-Compatible Destination Vectors 
 
Expression vectors are assembled from MammoBlocks by combining an L4R1 Promoter 
part with an L1L2 Gene part and an appropriate destination vector in a multisite 
Gateway© reaction. The only strict sequence requirement for the destination vector is the 
presence of attR4 and attR2 recombination sites. Other plasmid features useful for 
bacterial and mammalian cloning are listed below 
 
Basic Cloning:  
1) The presence of a E. Coli killing gene (e.g. ccdB) , flanked by attR4 and attR2 
recombination sites. This allows for the selection of correct plasmids during the 
transformation step following the recombination reaction.  
2) A bacterial origin of replication.  
 
Mammlian Cloning: 
 
3) Resistance genes against various mammalian-toxic antibiotics (e.g. hygromcin,  
puromycin.) 
4) A lentiviral origin of replication and lentiviral packaging sequences, for use in the 
creation of virus for infection into stable cell lines.  
 
 
 
MammoBlock Expression Vector Assembly 
 
A MammoBlock L4R1 Promoter Part, L1L2 Gene Part, and appropriate destination 
vector are combined in a multi-site Gateway© reaction to yield the final expression 
vector.  
 
Recombination Cloning Background:  
Two recombination reactions form the basis for the assembly cloning. The enzymes 
involved function in the lysogenic cycle of the temperate lambda bacteriophage. During 
the lysogenic cycle, lambda bacteriophage integrates its genome into the host E. coli 
genome. The enzymes that control this integration are integrase (Int), excisionase (Xis) 
and integration host factor (IHF). Integrase can mediate either excision or integration of 
the genome, catalyzed by IHF. The recombination sites involved are termed attB, attP, 
attL and attR; during integration, Int catalyzes the recombination of attB and attP sites to 
form an attL and attR sites flanking the integrated genome. The opposite reaction takes 
place for excision; the Int catalyzes the recombination of the attL and attR sites, yielding 
a liberated phage genome with an attP site, and the original host genome with an attB site 
The reaction equilibrium normally favors the attB and attP recombination. The 
excisionase Xis catalyzes excision by binding to the attR site and shifting the equilibrium 
to favor the reverse reaction.  
 
Assembly Reaction: 
The actual assembly reaction involves combing equimolar amounts of the part vectors 
with a mix of Integrase,  IHF,  and Excisionase enzymes to catalyze the recombination 
reaction. After 12-16 hours, the reaction is stopped with the addition of Proteinase K, and 
the product is then transformed into bacterial cells, for miniprepping to yield the final 
construct. The product of an assembly recombination reaction between the L4R1 TRET 
promoter vector and the L1L2 EGFP gene vector is shown below.  
 
 
 
 
 
Note: this plasmid is optimized for mammalian cloning; it contains appropriate selection 
markers and lentiviral sequences. The Ubc constitutive promoter controls  
expression of the puromycin resistance gene. The attB sites between the TRE promoter 
and the EGFP gene insert are the result of recombination between the attL and attR sites.  
 
Conclusion 
 
We present MammoBlock recombination cloning as the mammalian standard for part-
based assembly of expression vectors. The variety of methods for creating entry vectors, 
the robust nature of the reaction, and the quick time for completion combine to make this 
assembly a quick and efficient counterpart to the BioBricking standard.  
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